Bristol-Myers Squibb Company (BMY)vsHSBC Holdings PLC ADR (HSBC)
BMY
Bristol-Myers Squibb Company
$56.16
-0.16%
HEALTHCARE · Cap: $114.68B
HSBC
HSBC Holdings PLC ADR
$90.16
+1.34%
FINANCIAL SERVICES · Cap: $313.47B
Smart Verdict
WallStSmart Research — data-driven comparison
HSBC Holdings PLC ADR generates 32% more annual revenue ($63.77B vs $48.48B). HSBC leads profitability with a 35.0% profit margin vs 15.0%. HSBC appears more attractively valued with a PEG of 1.23. HSBC earns a higher WallStSmart Score of 61/100 (C+).
BMY
Buy60
out of 100
Grade: C+
HSBC
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.0%
Fair Value
$88.08
Current Price
$56.16
$31.92 discount
Intrinsic value data unavailable for HSBC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 39 in profit
Strong operational efficiency at 33.0%
Large-cap with strong market position
Attractively priced relative to earnings
Mega-cap, among the largest globally
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.7%
Attractively priced relative to earnings
Areas to Watch
2.6% revenue growth
Expensive relative to growth rate
Distress zone — elevated risk
Elevated debt levels
3.3% revenue growth
2.6% earnings growth
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BMY
The strongest argument for BMY centers on Return on Equity, Operating Margin, Market Cap.
Bull Case : HSBC
The strongest argument for HSBC centers on Market Cap, Profit Margin, Operating Margin. Profitability is solid with margins at 35.0% and operating margin at 49.7%. PEG of 1.23 suggests the stock is reasonably priced for its growth.
Bear Case : BMY
The primary concerns for BMY are Revenue Growth, PEG Ratio, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Bear Case : HSBC
The primary concerns for HSBC are Revenue Growth, EPS Growth, Altman Z-Score. Debt-to-equity of 2.79 is elevated, increasing financial risk.
Key Dynamics to Monitor
HSBC carries more volatility with a beta of 0.57 — expect wider price swings.
HSBC is growing revenue faster at 3.3% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HSBC scores higher overall (61/100 vs 60/100), backed by strong 35.0% margins. BMY offers better value entry with a 32.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →HSBC Holdings PLC ADR
FINANCIAL SERVICES · BANKS - DIVERSIFIED · USA
HSBC Holdings plc offers banking and financial products and services globally. The company is headquartered in London, the United Kingdom.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?